Old retatrutide pen: still safe to use?

A question that comes up often on peptide forums: someone bought a pen of retatrutide months ago, used it once or twice, then left it untouched, and the box carries a printed expiry date years out. Is it still fine to use? The honest starting point is that "still within the printed date" and "still good to use" are two different questions once a pen has been opened. Retatrutide has no approved manufacturer label of its own to answer that second question, so the useful move is to look at how the label works on the nearest peptide pen that does have one, then be direct about where that comparison stops helping.

The printed date only covers an unopened, refrigerated pen

Take Mounjaro (tirzepatide), the closest FDA-approved comparator with public prescribing information. Its DailyMed label states that an unopened pen or vial can be used until the printed expiration date only if it stays refrigerated at 2 to 8 degrees C the whole time. Stored at room temperature instead, the clock changes: an unopened pen kept at up to 30 degrees C must be thrown away after 30 days, regardless of the printed date on the box.^[1]

Once a pen has actually been opened and used, a third and shorter clock takes over. The label instructs patients to throw away an opened pen after a total of 30 days at room temperature, 30 days after first use, or after four weekly doses, whichever comes first, even if medicine is left in it.^[1] Two doses taken months ago, then a pen left sitting in a drawer, already runs past all three of those limits on the one comparable product that actually publishes numbers.

What that means for a pen used once or twice, then forgotten

We don't have a retatrutide-specific stability study to cite here, and we're not going to pretend one exists. What we can say is that the Mounjaro pattern is not an outlier. Approved incretin-receptor pens tend to define an in-use window measured in weeks, not months, because a peptide in solution degrades faster once it leaves refrigerated storage. Heat and time both push the molecule toward losing potency or breaking down through oxidation, deamidation, or aggregation. A pen that was opened, used a couple of times, and then sat at room temperature for months describes a storage history well outside any in-use window that a labeled, comparable product allows.

Retatrutide doesn't have a label to check against

Retatrutide itself remains investigational. The United States government's ClinicalTrials.gov registry describes its key Phase 3 obesity trial, TRIUMPH-1, as a randomized, placebo-controlled study of an experimental compound, not a marketed medicine.^[2] Mounjaro's own authorization by the EMA in September 2022 is exactly the kind of process retatrutide has not completed anywhere we track.^[3] The fuller country-by-country regulatory picture is on our retatrutide regulation page.

A real manufacturer label is not a courtesy. It comes out of a stability program: the company tests its actual formulation at set temperatures and time points and sets the in-use window based on when it starts to lose potency. Retatrutide has no equivalent public program to check. What is sold online as a retatrutide pen is typically a compounded or research-labeled product prepared outside that framework, so there is no comparable document, and the storage history before it reached the buyer, how it was shipped, whether the cold chain held, how long it sat in inventory, is usually unknown too.

What we don't yet know

We don't know retatrutide's actual in-use stability profile, because no public stability study or manufacturer beyond-use date exists for it the way one exists for Mounjaro. We don't know the storage history of any specific vial or pen bought outside a regulated pharmacy supply chain. And whether a given compounded product was accurately dosed, or purely retatrutide in the first place, is a separate question from storage, but it sits underneath the same worry. Treat a printed expiry date on a pen like this as the outer limit of an unopened, correctly refrigerated product, not as a guarantee covering a pen that has already been opened, used, and left at room temperature for months.

If you're not sure, don't guess

General medicine guidance applies here, and it is not complicated. The U.S. National Library of Medicine's MedlinePlus advises checking the expiration date and throwing out medicine that is past it, and not using anything that has changed color, texture, or smell even if it has not technically expired yet.^[4] A pen opened months ago, with no label to define its own in-use window and no way to confirm its storage history since, fits that caution before the printed date even becomes the question.

If you are weighing whether to keep using a pen like this, the useful next step is a conversation with the pharmacy or compounder that supplied it about their specific beyond-use dating, not a guess based on the box. And if that conversation isn't possible or the answer is uncertain, the safer default with any investigational, unregulated peptide product is to discard it through a proper medicine take-back option rather than use it. Our tirzepatide and retatrutide pages cover the fuller evidence and regulatory picture, including why an unregulated supply chain is itself part of the risk.